Having trouble accessing articles? Reset your cache.

Exelixis, Bristol-Myers deal

Exelixis granted Bristol-Myers exclusive, worldwide rights to develop and commercialize preclinical small molecule G protein-coupled bile acid receptor 1 ( GPBAR1; TGR5)

Read the full 228 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE